Trending Now
Business
Mylan Calls Allergan’s Mohawk Deal A ‘Sham’
Allergan (AGN) is suing generic drug makers Mylan (MYL) and Teva (TEVA) for patent infringement pursuant to Restasis, its blockbuster dry eye treatment. An...
Mallinckrodt: Former Employee Blows The Whistle On Acthar
Mallinckrodt (MNK) is currently under siege from Praxair (PX) who is seeking to sell a generic version of its top-selling treatment Inomax. A Delaware...
Lifestyle today
Entertainment
Endo’s Bonds Are Rallying
Endo International (ENDP) is still one of the market's most frustrating, confounding stocks. The stock hit a 52-week high of over $18 in the...
Trump And The GE: 8 Barbarians At The Gate For Endo (#8)
Endo International appears to really be going through it. The generic pharmaceutical company is exposed to opioid litigation after having sold Opana...
Did Obama Call Trump A Nazi Sympathizer?
The mid-term elections are in full throttle and a lot is on the table. For President Trump, if the democrats retake the house it...
Weatherford Earnings Preview
Weatherford International (WFT) reports quarterly earnings April 24th. Analysts expect revenue of $1.46 billion and eps of -$0.22. The revenue estimate implies flat revenue...
General Electric: Did ‘Run On The Bank’ Force A GECAS Sale?
Shares in General Electric (GE) spiked more than 6% Monday on market chatter that Apollo Global Management was interested in acquiring GE Capital Aviation...
Johnson & Johnson’s COVID-19 Vaccine Could Punish Moderna, Novavax
Back in November it was uncertain whether big pharma could develop a vaccine to combat the coronavirus. Today at least four firms have garnered...
ESPN Suspends Jemele Hill For Talking Reckless
The war between President Trump, black athletes, NFL owners, the flag, the Anthem, et. al has reached a fever pitch. It appears ESPN commentator...
Salesforce.com Q2: The One Metric That Matters
Salesforce.com (CRM) reports quarterly earnings after hours. Analysts expect revenue of $2.51 billion and EPS of $0.32. The revenue estimate implies 23% growth Y/Y....























































































































